Cargando…

VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells

BACKGROUND: Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic neoplastic disorder caused by germline mutation or deletion of the VHL gene, characterized by the tendency to develop multisystem benign or malignant tumors. The mechanism of VHL mutants in pathogenicity is poorly understan...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xueyou, Tan, Zenglai, Zhang, Qin, Ma, Kaifang, Xiao, Jun, Wang, Xiong, Wang, Yanan, Zhong, Mengjie, Wang, Yu, Li, Jing, Zeng, Xing, Guan, Wei, Wang, Shaogang, Gong, Kan, Wei, Gong-Hong, Wang, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066845/
https://www.ncbi.nlm.nih.gov/pubmed/35505422
http://dx.doi.org/10.1186/s13578-022-00790-x
_version_ 1784699880642445312
author Ma, Xueyou
Tan, Zenglai
Zhang, Qin
Ma, Kaifang
Xiao, Jun
Wang, Xiong
Wang, Yanan
Zhong, Mengjie
Wang, Yu
Li, Jing
Zeng, Xing
Guan, Wei
Wang, Shaogang
Gong, Kan
Wei, Gong-Hong
Wang, Zhihua
author_facet Ma, Xueyou
Tan, Zenglai
Zhang, Qin
Ma, Kaifang
Xiao, Jun
Wang, Xiong
Wang, Yanan
Zhong, Mengjie
Wang, Yu
Li, Jing
Zeng, Xing
Guan, Wei
Wang, Shaogang
Gong, Kan
Wei, Gong-Hong
Wang, Zhihua
author_sort Ma, Xueyou
collection PubMed
description BACKGROUND: Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic neoplastic disorder caused by germline mutation or deletion of the VHL gene, characterized by the tendency to develop multisystem benign or malignant tumors. The mechanism of VHL mutants in pathogenicity is poorly understand. RESULTS: Here we identified heterozygous missense mutations c.193T > C and c.194C > G in VHL in several patients from two Chinese families. These mutations are predicted to cause Serine (c.193T > C) to Proline and Tryptophan (c.194C > G) substitution at residue 65 of VHL protein (p.Ser65Pro and Ser65Trp). Ser65 residue, located within the β-domain and nearby the interaction sites with hypoxia-inducing factor α (HIFα), is highly conserved among different species. We observed gain of functions in VHL mutations, thereby stabilizing HIF2α protein and reprograming HIF2α genome-wide target gene transcriptional programs. Further analysis of independent cohorts of patients with renal carcinoma revealed specific HIF2α gene expression signatures in the context of VHL Ser65Pro or Ser65Trp mutation, showing high correlations with hypoxia and epithelial-mesenchymal transition signaling activities and strong associations with poor prognosis. CONCLUSIONS: Together, our findings highlight the crucial role of pVHL-HIF dysregulation in VHL disease and strengthen the clinical relevance and significance of the missense mutations of Ser65 residue in pVHL in the familial VHL disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00790-x.
format Online
Article
Text
id pubmed-9066845
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90668452022-05-04 VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells Ma, Xueyou Tan, Zenglai Zhang, Qin Ma, Kaifang Xiao, Jun Wang, Xiong Wang, Yanan Zhong, Mengjie Wang, Yu Li, Jing Zeng, Xing Guan, Wei Wang, Shaogang Gong, Kan Wei, Gong-Hong Wang, Zhihua Cell Biosci Research BACKGROUND: Von Hippel-Lindau (VHL) disease is an autosomal dominant genetic neoplastic disorder caused by germline mutation or deletion of the VHL gene, characterized by the tendency to develop multisystem benign or malignant tumors. The mechanism of VHL mutants in pathogenicity is poorly understand. RESULTS: Here we identified heterozygous missense mutations c.193T > C and c.194C > G in VHL in several patients from two Chinese families. These mutations are predicted to cause Serine (c.193T > C) to Proline and Tryptophan (c.194C > G) substitution at residue 65 of VHL protein (p.Ser65Pro and Ser65Trp). Ser65 residue, located within the β-domain and nearby the interaction sites with hypoxia-inducing factor α (HIFα), is highly conserved among different species. We observed gain of functions in VHL mutations, thereby stabilizing HIF2α protein and reprograming HIF2α genome-wide target gene transcriptional programs. Further analysis of independent cohorts of patients with renal carcinoma revealed specific HIF2α gene expression signatures in the context of VHL Ser65Pro or Ser65Trp mutation, showing high correlations with hypoxia and epithelial-mesenchymal transition signaling activities and strong associations with poor prognosis. CONCLUSIONS: Together, our findings highlight the crucial role of pVHL-HIF dysregulation in VHL disease and strengthen the clinical relevance and significance of the missense mutations of Ser65 residue in pVHL in the familial VHL disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13578-022-00790-x. BioMed Central 2022-05-03 /pmc/articles/PMC9066845/ /pubmed/35505422 http://dx.doi.org/10.1186/s13578-022-00790-x Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ma, Xueyou
Tan, Zenglai
Zhang, Qin
Ma, Kaifang
Xiao, Jun
Wang, Xiong
Wang, Yanan
Zhong, Mengjie
Wang, Yu
Li, Jing
Zeng, Xing
Guan, Wei
Wang, Shaogang
Gong, Kan
Wei, Gong-Hong
Wang, Zhihua
VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title_full VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title_fullStr VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title_full_unstemmed VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title_short VHL Ser65 mutations enhance HIF2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
title_sort vhl ser65 mutations enhance hif2α signaling and promote epithelial-mesenchymal transition of renal cancer cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9066845/
https://www.ncbi.nlm.nih.gov/pubmed/35505422
http://dx.doi.org/10.1186/s13578-022-00790-x
work_keys_str_mv AT maxueyou vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT tanzenglai vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT zhangqin vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT makaifang vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT xiaojun vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT wangxiong vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT wangyanan vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT zhongmengjie vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT wangyu vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT lijing vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT zengxing vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT guanwei vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT wangshaogang vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT gongkan vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT weigonghong vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells
AT wangzhihua vhlser65mutationsenhancehif2asignalingandpromoteepithelialmesenchymaltransitionofrenalcancercells